NCBiotech News

Sign up now for NCBiotech-hosted CRO Career Conversations, to be held March 17 from 6 to 7 p.m. on March 17 with a focus on contract research associates, a key position that is heavily involved in monitoring clinical trials.

Today marks International Women’s Day: a day devoted to celebrating women, their achievements and recognizing the bias that holds many back. The North Carolina life sciences community owes many successes to the women who devote their talents to public health.

Durham’s 410 Medical, Inc. has launched sales in the United States of its LifeFlow PLUS Blood and Fluid Infuser, following its U.S. Food and Drug Administration clearance in 2020.

Biogen has announced a $200 million investment to support clinical production for its gene therapy pipeline. The company plans to add 90 more workers to its workforce of 1,900 people at its two facilities in the Research Triangle Park.

Expansions announced in 2020 will bring more than $2.3 billion in investment and 2,800 new jobs in biopharma manufacturing to North Carolina in coming months and years.

West Pharmaceutical Services, a manufacturer of drug-packaging and delivery components in Kinston for the last four decades, will invest $19 million, add 90 workers over the next year to expand its production capacity there.

Morrisville gene editing startup Locus Biosciences has completed the world’s first clinical trial of a recombinant bacteriophage therapy that also marks the first time a CRISPR-enhanced therapeutic has been administered in a clinical setting.

North Carolina's Research Triangle, birthplace and global centerpiece of the huge contract research enterprise, is losing a homegrown headquarters with a $12 billion buyout of PRA Health Sciences by Ireland-based ICON plc.

Pittsboro-based startup Propella Therapeutics is teaming up with the National Cancer Institute (NCI) to evaluate its new treatment for metastatic prostate cancer.

Sam Taylor, a founder and long-time president of the state's life sciences trade association, NCBIO, has died of pancreatic cancer.

[Editor's note from Tracey du Laney, Ph.D., the North Carolina Biotechnology Center’s senior director of Science and Technology Development, who oversees this grant: This line of research exemplifies what a Flash Grant is all about. The nanosphere  technology that Dr. Brown’s team is developing addresses a large patient population with unmet needs in a new way. It could lead to new therapeutics to treat disseminated intravascular coagulation (DIC). DIC results not just from sepsis and cancer, but also has emerged as a life-threatening condition with COVID-19.

Advanced Chemotherapy Technologies, a Raleigh medical device startup developing a way to improve the treatment of pancreatic cancer, has added $2.5 million in funding to support clinical testing of its technology.

Durham-based regenerative medicine company Humacyte is going public in a novel deal that will give it a market capitalization of $1.1 billion.

A drug being developed by Cary-based Rescindo Therapeutics for treating a rare developmental disorder in children has received two special designations from the FDA.

Life sciences manufacturing companies in North Carolina expanded their collective workforce by more than 11%.in 2020, in sharp contrast to the global economic downturn wrought by the COVID-19 pandemic.